1. Home
  2. Directory
  3. North Carolina
  4. Wilmington
  5. Ophthalmology
  6. NPI Profile
  7. Prescriptions 1154884716

NATHAN ALEXANDER FISCHER
Prescription History 1154884716
Ophthalmology in Wilmington, NC


Quality Rating: 100 out of 100 score

NPI Status: Active since April 10, 2019

Contact Information

3562 ANSLEY DRIVE
WILMINGTON, NC
ZIP 28412
Phone: (910) 332-3560

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for NATHAN ALEXANDER FISCHER, an active Ophthalmology specialist practicing in Wilmington, NC. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 55 documented patient claims. Among these therapy options, the most frequently utilized medication is Prednisolone Acetate, which accounts for 15 claims alone.

Medication Index

Brimonidine Tartrate

Generic Formulation: Brimonidine TartrateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 14
30-Day Fills 19.4
Days Supply 514
NC State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills123.1
Peer Average Days Supply3,548
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 79.4% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $675.46 across this reporting matrix range.

Provider Avg Cost Per Claim

$48.25

State Avg Cost Per Claim

$44.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.

Therapeutic Applications

This medication is used to treat open-angle glaucoma or high fluid pressure in the eye. Lowering high fluid pressure in the eye reduces the risk of vision loss, nerve damage, or blindness. This medication lowers pressure by allowing better fluid drainage from within the eye and also by reducing the amount of fluid formed in the eye. It is known as an alpha agonist. This drug is not recommended for use in children less than 2 years of age due to an increased risk of serious side effects such as very slowed breathing. Ask the doctor or pharmacist for details.

Difluprednate

Generic Formulation: DifluprednateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.5
Days Supply 196
NC State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills36.9
Peer Average Days Supply884
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 62.5% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,272.96 across this reporting matrix range.

Provider Avg Cost Per Claim

$106.08

State Avg Cost Per Claim

$161.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat swelling and pain after eye surgery. It may also be used to treat a certain serious eye problem (endogenous anterior uveitis). This medication belongs to a class of drugs known as corticosteroids.

Neomycin-Polymyxin-Dexameth

Generic Formulation: Neomycin/Polymyxin B/DexamethaSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 235
NC State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills49.4
Peer Average Days Supply708
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.8% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $283.98 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.28

State Avg Cost Per Claim

$14.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat conditions involving swelling (inflammation) of the eyes and to treat or prevent bacterial eye infections. This product contains neomycin and polymyxin, antibiotics that work by stopping the growth of bacteria. It also contains dexamethasone, an anti-inflammatory corticosteroid that works by reducing swelling. This medication treats/prevents only bacterial eye infections. It will not work for other types of eye infections and may worsen them (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.1
Days Supply 365
NC State Average Benchmarks
Peer Average Claims109.0
Peer Average 30-Day Fills141.6
Peer Average Days Supply3,630
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 86.2% less volume than the regional standard for practitioners inside NC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $950.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$63.35

State Avg Cost Per Claim

$48.59

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like NATHAN ALEXANDER FISCHER provides transparency into local medical care patterns within Wilmington, NC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.